Sequent Scientific Limited, now operating as Viyash Scientific Limited, has entered into a strategic partnership with Boehringer Ingelheim India Private Limited to expand its presence in India's companion animal healthcare market. The partnership, executed through Viyash Scientific's wholly owned subsidiary Alivira Animal Health Limited, focuses on distribution and promotion of Boehringer Ingelheim's companion animal products portfolio across India.

Strategic Partnership Details

The collaboration is designed to capture growing opportunities in India's pet healthcare market, which is experiencing significant growth driven by increased pet ownership, rising awareness of preventive care, and growing emphasis on animal well-being across the country.

Leadership Perspectives

Dr. Haribabu Bodepudi, MD & Group CEO of Viyash Scientific Limited, emphasized the significance of this partnership: "This represents an important milestone in Viyash Scientific's journey to become a key player in the companion animal segment. India offers tremendous opportunities for innovative medicines which cater to the medical needs of our pets."

Dr. Vinod Gopal, Country Head, Animal Health at Boehringer Ingelheim India, highlighted the strategic alignment: "This partnership aligns with our long-term growth strategy for the animal health business in India and enables us to serve our customers with greater clarity, consistency, and care."

Market Expansion Strategy

The partnership leverages the complementary strengths of both organizations:

• Alivira's Capabilities: Extensive geographical reach and on-ground capabilities across India
• Boehringer Ingelheim's Portfolio: Differentiated companion animal products and robust pipeline
• Combined Focus: Enhanced market reach, improved access, and execution excellence

Company Background

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is among the top 25 Animal Health companies globally. The company operates as an integrated pharmaceutical company with over 3,000 employees, serving customers in over 100 countries. The group maintains manufacturing, R&D, and distribution operations across India, Spain, Brazil, Turkey, and USA, with approvals from international regulatory bodies including USFDA, EUGMP, WHO, and TGA.

Boehringer Ingelheim, established in India in 2003, operates as a biopharmaceutical company active in both human and animal health, with more than 53,500 employees serving over 130 markets globally. The company focuses on developing innovative therapies in areas of high unmet medical need, with key therapy areas including diabetes, cardiovascular, and respiratory conditions.

Sequent Scientific Limited has announced a conference call with analysts and investors to discuss its Q3FY26 financial results. The earnings call is scheduled for February 6, 2026, at 9:00 AM IST, as communicated to BSE Limited and National Stock Exchange of India Limited on January 21, 2026.

Regulatory Compliance and Announcement Details

The company made this announcement pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal intimation was signed by Yoshita Vora, Company Secretary & Compliance Officer, and submitted to both stock exchanges where the company is listed.

Conference Call Leadership

The Q3FY26 earnings discussion will be led by the company's senior management team, ensuring comprehensive coverage of financial performance and business developments.

Participation Details

Investors and analysts can participate in the conference call using the provided dial-in numbers. The company has made arrangements for universal access and early registration through DiamondPass facility.

Company Information

Sequent Scientific Limited, formerly known as Viyash Scientific Limited, operates in the animal health sector. The company's registered office is located at 3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033. Additional information and conference call details are available on the company's website in the Investors Section at www.sequent.in .